Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
Total Valuation
Context Therapeutics has a market cap or net worth of $116.69M. The enterprise value is $15.42M.
Market Cap$116.69M
Enterprise Value$15.42M
Share Statistics
Context Therapeutics has 91,879,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding91,879,170
Owned by Insiders1.35%
Owned by Institutions63.99%
Financial Efficiency
Context Therapeutics’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -31.34%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-31.34%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee0.00
Profits Per Employee-2.23M
Employee Count12
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Context Therapeutics is ―. Context Therapeutics’s PEG ratio is 0.03.
PE Ratio―
PS Ratio0.00
PB Ratio0.64
Price to Fair Value0.64
Price to FCF-2.09
Price to Operating Cash Flow-16.00
PEG Ratio0.03
Income Statement
In the last 12 months, Context Therapeutics had revenue of 0.00 and earned -26.73M in profits. Earnings per share was -0.46.
Revenue0.00
Gross Profit0.00
Operating Income-29.92M
Pretax Income-26.73M
Net Income-26.73M
EBITDA-29.91M
Earnings Per Share (EPS)-0.46
Cash Flow
In the last 12 months, operating cash flow was -22.35M and capital expenditures -33.95K, giving a free cash flow of -22.38M billion.
Operating Cash Flow-22.35M
Free Cash Flow-22.38M
Free Cash Flow per Share-0.24
Dividends & Yields
Context Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change29.59%
50-Day Moving Average1.17
200-Day Moving Average0.88
Relative Strength Index (RSI)64.95
Average Volume (3m)546.98K
Important Dates
Context Therapeutics upcoming earnings date is Mar 25, 2026, After Close (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateMar 25, 2026
Ex-Dividend Date―
Financial Position
Context Therapeutics as a current ratio of 35.62, with Debt / Equity ratio of 0.20%
Current Ratio35.62
Quick Ratio35.62
Debt to Market Cap<0.01
Net Debt to EBITDA3.53
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Context Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Context Therapeutics EV to EBITDA ratio is 1.23, with an EV/FCF ratio of 1.12.
EV to Sales0.00
EV to EBITDA1.23
EV to Free Cash Flow1.12
EV to Operating Cash Flow2.26
Balance Sheet
Context Therapeutics has $76.94M in cash and marketable securities with $140.20K in debt, giving a net cash position of $76.80M billion.
Cash & Marketable Securities$76.94M
Total Debt$140.20K
Net Cash$76.80M
Net Cash Per Share$0.84
Tangible Book Value Per Share$1.63
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Context Therapeutics is $4.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.67
Price Target Upside267.72% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast69.30%